Vietnam, US Trade Deal Could Be Signed Soon, To Lam Says 
Wall Street Falls as Treasury Yields Surge, Oil Rebounds on Iran Tensions 
South Korea, US Discuss Warship Building Cooperation 
China Vanke Shares Jump as Beijing Moves to Ease Debt Pressure 
Telix to Acquire Germany’s ITM in $1.65 Billion Radiopharma Deal 
Goldman Sachs Names Simon Lyons UK Investment Banking Co-Head 
Asian Stocks Mixed Ahead of Trump-Xi Meeting 
Oil Prices Tumble on U.S.-Iran Diplomacy Hopes, Supply Relief 
McDonald’s Sees Flat Traffic, Sticky Inflation as New Normal 
Oil Prices Ease as Iran Tensions Clash With Diplomacy Hopes 
NASA, Boeing Discuss Expanding Starliner Missions 
Yen Weakens as Dollar Gains on Widening US-Japan Rate Gap 
fnny Beta Launches With a Simple Idea: Find an Event, Show Up, Get Rewarded 
Petrobras Joins Brazil Diesel Subsidy Program 
White House Bars CNN, MS NOW and Politico Reporters 
Japan Private-Sector Growth Slows as Domestic Demand Weakens 
US Dollar Hits Two-Month High as Fed Rate Hike Bets Rise 
Add as a preferred source on Google
Celltrion’s antibody treatment for COVID-19 has been granted approval for emergency use in Peru. The South Korean pharmaceutical company announced on Monday, Nov. 22, that the Peruvian authorities approved its Regkirona treatment for emergency application on adult patients with COVID-19.
According to Yonhap News Agency, Peru authorized Celltrion’s antibody treatment for emergency use based on recent results of phase three clinical study of the drug. The study was for attaining more comprehensive results for Regkirona’s effectiveness and safety, and since the results were good, it was approved.
The antibody treatment is being administered to patients in the form of an intravenous injection. It was said to be directly injected for 60 minutes.
Peru is the latest country to issue approval on Celltrion’s drug for treating COVID-19. It has already won approval from other states, such as Brazil and Indonesia, for emergency application. In its home base, which is South Korea, Regkirona has already won the authorities’ drug safety conditional approval in February.
One of the best things about the new drug is that it can lower the risk of COVID-19’s progress to severe levels. What’s more, Celltrion previously stated that its antibody treatment could also reduce the recovery time of patients.
Celltrion’s Regkirona is also South Korea’s very first COVID-19 treatment and it secured approval from Peru just a week after receiving marketing approval from the European Commission. The monoclonal antibody treatment was given the go-ahead last week.
Today’s achievement, coupled with Committee for Medicinal Products for Human Use (CHMP) positive opinion for Regdanvimab, underscores our ongoing commitment to addressing the world’s greatest health challenges,” Celltrion Healthcare’s head of medical and marketing, Dr. HoUng Kim, Ph.D., said in a press release. “Typically, the recommendations from the CHMP are passed on to the EC for rapid legally binding decisions within a month or two, however, given the unprecedented times, we have received the EC approval within a day.”
Meanwhile, the medical and marketing chief added that they are currently in talks with contractors and governments in 30 countries more across Asia, Europe, and Latin America. Celltrion said it would continue to work to make sure that COVID-19 patients worldwide will have access to safe and effective treatment.
